Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway

BackgroundFruquintinib, a selective vascular endothelial growth factor receptor (VEGFR) inhibitor, has shown considerable efficacy in colorectal cancer (CRC) treatment. Despite its promising therapeutic effects, the precise molecular mechanisms underlying its therapeutic effects remain incompletely...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Qinqin Song, Hongjiao Wu, Ye Jin, Junzhi Hou, Jiawei Liu, Xuemei Zhang, Wanning Hu, Guogui Sun, Zhi Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Subjects:	fruquintinib colorectal cancer epithelial-mesenchymal transition (EMT) TGF-β/Smad signaling pathway vascular endothelial growth factor Receptor (VEGFR)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1503133/full